Gynecologic Oncology Pharmacology Research Program
Over the past four years, Director Judith Smith, Pharm.D., BCOP, has established a strong foundation for her research program focusing on new agents and new combinations of agents for the treatment of gynecologic malignancies. Dr. Smith's research also has focused on mechanisms of drug resistance and aspects of drug toxicity associated with drug metabolism and plasma protein binding drug interactions that effect therapeutic outcomes. Dr. Smith and her research team are critical component of translational research projects to implement findings into clinical practice and vice versa to enhance the clinical perspective in the direction of laboratory research projects in the gynecologic oncology arena.
Pharmacology Research Program Goal
To discover the optimal combination of chemotherapeutic agents while minimizing toxicity to improve response rates and prolong overall survival for patients with gynecologic malignancies.
Pharmacology Research Program Focus
New Drug Development
- New molecular entities
- New combinations of traditional chemotherapy agents for the treatment of gynecologic malignancies
- Emphasis on defining drug interactions involving the cytochrome P450 enzyme system, plasma protein binding and mechanisms of drug resistance and how these ultimately influence pharmacokinetic parameters, pharmacodynamics and efficacy